Purdue Pharma—John Brownlee and His Prosecution Team

Purdue Pharma—John Brownlee and His Prosecution Team describes an adversarial relationship between a pharmaceutical company determined to defend its OxyContin marketing and federal prosecutors who built a criminal case in western Virginia. Beginning in 2003, John Brownlee’s office gathered a large documentary record and, with prosecutors Randy Ramseyer and Rick Mountcastle, pursued a charge that did not require the government to prove that Purdue’s marketing had caused particular overdoses or cases of addiction. The investigation culminated in a 2007 plea agreement: narrower than the prosecution’s initial ambitions, but a criminal resolution requiring Purdue Frederick to plead guilty to felony misbranding and three senior executives to plead guilty to misdemeanors.

A small office takes on Purdue

John Brownlee was working toward a case against Purdue as early as 2003, while leading the U.S. attorney’s office in western Virginia. A former paratrooper and Army Reserve JAG Corps captain, he was thirty-six and politically ambitious. His prosecutorial approach was forceful and public-facing; his office’s effort against Purdue, by contrast, would depend on patient investigation and extensive records. The distinction mattered: the company faced not merely a dramatic courtroom contest but a federal team assembling evidence over years.

Brownlee brought prosecutors in from neighboring jurisdictions and designated them as special assistants to handle other cases, freeing his office to concentrate on the Purdue investigation. He selected assistant U.S. attorneys Randy Ramseyer and Rick Mountcastle to lead it. They were career government lawyers based in Abingdon, three hours west of Brownlee and closer to the coalfields, and neither relied on press attention. Their work joined Brownlee’s broader effort to a team whose methods were painstaking rather than theatrical.

The Abingdon prosecutors had already seen the effects of OxyContin’s introduction in their caseloads. Before the Purdue case, they had successfully prosecuted ten doctors, pharmacists, and dentists for overprescribing drugs, including to children as young as nine. In the Purdue investigation, nine state and federal agencies would work for five years to build the case. The prosecutors’ experience with medical overprescribing supplied local context, while the scale of the interagency investigation gave them the capacity to examine the company’s conduct itself.

Building the criminal case

The legal theory helped define the prosecution’s contest with Purdue. The federal government needed to prove that the drug had been criminally misbranded: a technical, broad charge covering false labeling, fraudulent promotion, or marketing a drug for an unapproved use. It did not have to establish that the alleged misbranding directly caused overdose, addiction, or misuse. That distinction made the case different from civil claims seeking to connect the company’s conduct to particular injuries, and it gave the prosecutors a route toward criminal accountability even without proving individual causation.

The office worked through millions of records, cataloguing material in spreadsheets and drawing on case files and sales-representative notes gathered in earlier litigation. The accumulated documents supported the prosecutors’ belief that Purdue had knowingly concealed the drug’s addictiveness. In 2005, after news of a federal grand jury investigation became public, the company’s legal challenge was no longer simply a defense against individual lawsuits: the prosecution was developing a criminal account from a vast documentary record.

Brownlee’s team also had to withstand pressure from outside the district. During settlement negotiations, Rudy Giuliani made multiple calls on Purdue’s behalf, seeking to unsettle the younger prosecutor. Brownlee prepared for their first meeting by reading Giuliani’s book, but maintained that the office’s size and location did not determine whether it could succeed. The negotiations thus placed the small-town prosecutors opposite a company able to enlist a nationally prominent lawyer, while the underlying case continued to depend on the evidence Ramseyer and Mountcastle were assembling.

By the fall of 2006, prosecutors believed the evidence might support indicting Purdue and its top executives on felony charges beyond misbranding, including mail fraud, wire fraud, and money laundering. A memorandum to Brownlee conveyed the seriousness of that possibility. As the matter moved through Department of Justice headquarters, however, the potential charges were reduced. Purdue’s representatives lobbied against felony indictments for the executives, and the proposed corporate fine also became a point of negotiation: Purdue initially offered $10 million, while the government initially proposed $1 billion.

A negotiated and narrowed resolution

The scope of the threatened prosecution was not the only pressure on the negotiations. In 2005, Purdue’s lawyers contacted then-deputy attorney general James Comey to challenge Brownlee’s investigative tactics. Comey raised concerns with Brownlee, who drove to Washington to explain the office’s strategy. The episode illustrates the different kinds of leverage surrounding the case: prosecutors had the prospect of serious charges, while Purdue’s lawyers could try to influence how senior officials assessed the investigation.

Rather than face the possibility of more serious charges or a jury trial in western Virginia, Purdue accepted the plea agreement. The resolution was substantially narrower than the case the prosecutors had initially contemplated. Purdue Frederick, a Purdue-owned holding company, pleaded guilty to a single felony count of misbranding. Paul Goldenheim, Michael Friedman, and Howard Udell pleaded guilty to misdemeanor misbranding charges. The executives did not stipulate that they had direct knowledge of the misbranding; instead, the plea language allowed the court to accept the stated facts in support of their pleas. The distinction preserved a gap between the criminal responsibility assigned to the company and the executives’ acknowledged personal knowledge.

The settlement announced by Brownlee in downtown Roanoke in May 2007 resolved federal criminal and civil misbranding charges. Purdue agreed to pay $600 million in fines and admitted that, over six years, it had fraudulently marketed OxyContin as less prone to abuse and as having fewer narcotic side effects than immediate-release versions. The executives’ $34.5 million in fines was paid by the firm on their behalf, and their pleas were to misdemeanor versions of the offense. Purdue’s fines represented about 90 percent of the company’s profits from the drug’s 1996 launch through 2001, the year it dropped insert language claiming that the timed-release mechanism could reduce a drug’s abuse liability. The fine ranked as the eleventh-largest paid by a pharmaceutical firm in the Justice Department’s history.

Limits and consequences

The agreement fell short of the prosecutors’ original ambitions: the government had initially sought a $1 billion corporate fine and multiple felony charges against both the company and its executives. It also meant that the executives would serve no jail time under the agreement, although a judge retained authority to approve the deal and determine probation and community service at sentencing. For the prosecution team, the result was therefore neither the full set of charges once considered nor an absence of criminal accountability. The negotiated outcome imposed a felony plea on Purdue Frederick and misdemeanor pleas on its senior executives, while leaving the dispute over their direct knowledge unresolved in the plea language.

A sentencing hearing in Abingdon was planned for July, where grieving parents were invited to speak in court about the harm they attributed to OxyContin. That prospect connected the prosecutors’ legal resolution to the families’ experience of the epidemic: the case was not only about corporate marketing language and statutory classifications, but also about whether those affected could address the company’s leaders in a formal public setting. The eventual relationship between Purdue and Brownlee’s team is defined by that tension. A determined local prosecution converted years of accumulated records into a federal guilty plea, but the negotiated limits of the deal left the most sweeping threatened charges—and imprisonment for the executives—outside its terms.